We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers should consider the effects of price harmonization in the Persian Gulf region when deciding where to launch their products in the global marketplace, a new report concludes. Read More
Subsidiaries of generics maker Hetero Drugs can move forward with generic versions of the kidney drug PhosLo despite an ongoing lawsuit brought by patent owner Roxane Laboratories. Read More
Endo Pharmaceuticals and Impax Laboratories are facing a second proposed class action lawsuit over an alleged pay-to-delay deal that put off a generic launch of Endo’s pain medication Opana ER. Read More
A patient advocacy group is using a recently created review pathway through the U.S. Patent and Trademark Office to challenge the patent on Wyeth’s antibiotic Tygacil outside a Hatch-Waxman ANDA. Read More
Mylan and Sandoz have filed a legal brief with the U.S. Supreme Court challenging Teva’s appeal to salvage the patent protection on its blockbuster multiple sclerosis drug Copaxone. Read More
Generic versions of Depomed’s shingles drug Gralise are unlikely in the near future after a federal judge sided with the brand manufacturer’s patent infringement suit against a 2012 ANDA filed by Actavis. Read More
Alabama’s Supreme Court Aug. 15 reaffirmed its ruling that a brand drugmaker can be held liable for damages caused by a generic version of its product if the generic carries warning labels that are drafted by the brand company. Read More
1.7 million treatments will be sent to Burkina Faso, the Democratic Republic of Congo, Burundi, Nigeria, Liberia and Niger in the coming months. Read More
Actavis has launched a generic challenge against UCB’s Parkinson’s disease drug Neupro, and is facing a patent infringement lawsuit as a result. Read More
Generic versions of Ferring Pharmaceutical’s menstrual bleeding drug Lysteda can move forward after the brandmaker lost a pair of appeals in patent infringement lawsuits seeking to block ANDAs against the product. Read More